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We describe here the application of a novel bovine interleukin-2 (IL-2) enzyme-linked immunosorbent assay (ELISA) for the
measurement of antigen-specific IL-2 in cattle naturally infected withMycobacterium bovis and in cattle vaccinated withMyco-
bacterium bovis BCG and then experimentally challenged with pathogenicM. bovis. Supernatants from whole-blood cultures
stimulated with mycobacterial antigen (bovine purified protein derivative [PPDB] or the peptide cocktail ESAT6-CFP10) were
assessed using a sandwich ELISA consisting of a new recombinant monoclonal fragment capture antibody and a commercially
available polyclonal anti-bovine-IL-2. The production of IL-2 was compared to the production of gamma interferon (IFN-) in
the same antigen-stimulated whole-blood supernatants. The data show that cattle infected withM. bovis produced quantifiable
levels of antigen-specific IL-2, while IL-2 levels in cattle vaccinated withM. bovis BCG did not. Furthermore, cattle vaccinated
withM. bovis BCG and then challenged with pathogenicM. bovis displayed a more rapid induction of IL-2 but ultimately had
lower levels of infection-induced IL-2 than did unvaccinated challenge control cattle. These data suggest that IL-2 responses are
not detectable post-BCG vaccination and that these responses may require infection with virulentM. bovis to develop. This may
be useful to differentiate infected cattle from uninfected or BCG-vaccinated cattle, although the overall sensitivity is relatively
low, particularly in single intradermal comparative cervical tuberculin (SICCT)-negative infected animals. Furthermore, the
strength of the IL-2 response may correlate with pathology, which poses interesting questions on the immunobiology of bovine
tuberculosis in contrast to human tuberculosis, which is discussed.
Despite a compulsory test and slaughter regime since 1950, bo-vine tuberculosis (BTB) has reached epidemic status in focal
areas of Great Britain, and the recently published “Bovine TB Eradi-
cation Programme for England” (https://www.gov.uk/government
/publications/bovine-tb-eradication-programme-for-england) par-
ticularly prioritizes the development of a TB cattle vaccine with an
associated test to differentiate between infected and vaccinated/pro-
tected animals (DIVA).
The gamma interferon (IFN-) test has been used in Great
Britain since 2006 as an ancillary test to the single intradermal
cervical comparative tuberculin skin test (SICCT) for the diagno-
sis of preclinical BTB in Great Britain. Recent research in both
human and bovine TB fields indicates that other cytokines pro-
duced in response to TB antigen-specific stimulation may be uti-
lized as potential diagnostic tools. For example, in BTB using both
IFN- and interleukin-1 (IL-1) responses to the peptide cock-
tail ESAT6-CFP10 (EC) (present in pathogenic mycobacteria, but
absent in BCG [1]) showed an increase in the sensitivity of detec-
tion of Mycobacterium bovis-infected cattle without compromis-
ing specificity (2).
In terms of IL-2, multifunctional CD4 T cells producing
more than one cytokine, including IFN-, tumor necrosis factor
alpha (TNF-), and IL-2, have been described in murine models
of protection against TB (3–5). Multifunctional T cells have been
identified in human TB and in some reports as potential correlates
of pathology and bacterial load (6–8), while Millington et al. (9)
described kinetic changes in T cells producing different cytokines
over time, and correlated IL-2-producing T cells with a protective
outcome. In keeping with a protective role for IL-2, more recently
reported studies have shown that IL-2-positive (multifunctional)
T cells are involved in subunit vaccine boosts of BCG-induced
protective immunity both in humans (10) and in mice (11).
Recently, multifunctional T cells (IFN-, TNF-, and IL-2)
have also been described in cattle naturally infected with M. bovis
(12), and previous work had demonstrated IL-2 activity in BTB,
both in natural and experimental infections (13, 14). However,
the IL-2 in these early reports was assessed using a T cell bioassay,
which lacks specificity.
Using a bespoke bovine IL-2-specific antibody identified using
recombinant phage display technology, we investigated this cyto-
kine more fully in BTB by generating a sandwich enzyme-linked
immunosorbent assay (ELISA) that incorporates the recombinant
monoclonal antibody with a commercially available polyclonal
reagent for bovine IL-2. The aim of this study therefore was to
apply this new IL-2 ELISA to the investigation of antigen-specific
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IL-2 production in whole-blood stimulation cultures, as used for
the assessment of IFN- in BTB. Results are shown for IL-2 and
IFN- production in cattle naturally infected with M. bovis, cattle
vaccinated with M. bovis BCG and challenged with pathogenic M.
bovis, and uninfected controls.
MATERIALS AND METHODS
Animals. (i) Comparison of SICCT-positive/IFN--positive naturally
infected cattle with M. bovis BCG-vaccinated and uninfected control
cattle. Included in this cohort were (i) 33 SICCT-positive, IFN--positive
naturally infected cattle; (ii) 31 cattle from Great Britain herds without a
TB breakdown for at least 4 years that had been vaccinated subcutane-
ously with approximately 106 CFU M. bovis BCG-1331 in a 0.5-ml dose
and sampled at 4 weeks (n 6), 8 weeks (n 20), or 10 months (n 5)
postvaccination (3 separate experiments); and (iii) 31 uninfected control
cattle from BTB-free herds also without a breakdown for at least 4 years
(15).
(ii) Performance of IL-2 in comparison with the IFN- test in
SICCT-negative surveillance cattle from Great Britain breakdown
herds. Sixty-six SICCT-negative/IFN--positive cattle were identified via
routine blood testing of Great Britain breakdown herds at AHVLA Lud-
dington between October and December 2012. These were compared
with 64 uninfected control cattle from BTB-free herds with no history of
breakdown in the past 4 years.
(iii) Longitudinal investigations of M. bovis-BCG vaccination and
challenge with M. bovis. Two separate BCG-vaccination/M. bovis-chal-
lenge experiments were included as follows.
(a) Experiment 1. Twenty-four animals were recruited from BTB-free
farms at 5 weeks of age. Sixteen animals were vaccinated subcutaneously
within 6 weeks of age with a 0.5-ml volume dose of approximately 106
CFU of BCG Danish (Statens Serum Institute, Copenhagen, Denmark).
All animals were challenged at approximately 7 months of age with 200
CFU of M. bovis AF2122/97 (AHVLA Weybridge) by the endobronchial
route, and blood samples were taken at 0, 2, 4, 6, and 8 weeks postchal-
lenge (16).
(b) Experiment 2. Nine animals of 4 to 6 months of age were recruited
from BTB-free farms. Five were vaccinated subcutaneously with a 0.5-ml-
volume dose of approximately 106 CFU of BCG Danish (Statens Serum
Institute, Copenhagen, Denmark). Twelve weeks later these 5 animals
plus a further 4 unvaccinated controls were challenged with 12,200 CFU
M. bovis AF2122/97 (AHVLA Weybridge) by the endobronchial route.
Blood samples from this experiment were taken at 0, 3, 6, 8, and 12 weeks
post-BCG and at 2, 4, 7, and 11 weeks post-M. bovis challenge.
The M. bovis inoculum was prepared from a frozen seed stock at
known concentrations and the administered doses were confirmed retro-
spectively by culture as described previously (16). M. bovis BCG was pre-
pared fresh from lyophilized stocks on the day of vaccination according to
the manufacturer’s instructions and administered subcutaneously as de-
scribed previously (16).
Whole-blood IFN- and IL-2 assays. Supernatants were generated
from whole heparinized blood stimulated in vitro with (i) bovine tuber-
culin (bovine purified protein derivative [PPDB]) (Lelystad, Nether-
lands) at a 300-U/ml final concentration; (ii) peptide cocktails ESAT6-
CFP10 and Rv3615c (Pepseuticals, Leicestershire, United Kingdom) at a
final concentration of 5 g/ml; and (iii) the mitogen (sample positive
control) staphylococcal enterotoxin B (SEB) (Sigma, United Kingdom) or
pokeweed mitogen (PWM) (Sigma, United Kingdom) at a final concen-
tration of 2 g/ml or 10 g/ml, respectively. Unstimulated whole-blood
cultures provided the background negative sample controls. We added
250l of whole blood, in duplicate wells of 96-well plates (Nunc, Thermo
Fisher Scientific, United Kingdom) to 25l of 11 concentrated antigen,
mitogen, or medium only. Cultures were incubated for 16 to 24 h at 37°C,
5% CO2. Plates were then centrifuged at 300  g for 5 min at room
temperature (RT) to pellet the cellular fraction, and cell-free supernatants
were harvested and duplicates pooled and stored at	20°C.
(i) IFN- ELISA. IFN- content of the supernatants was measured
using the BOVIGAM ELISA kit (Prionics, Switzerland) following the
manufacturer’s instructions. Samples were tested in duplicate and the 

optical density (OD) at 450 nm was calculated for each stimulated super-
natant for each animal (i.e., the mean OD of sample duplicate in the
presence of antigen/mitogen minus the mean OD in the absence of anti-
gen/mitogen).
(ii) IL-2 ELISA. Flat-bottomed 96-well ELISA plates (Nunc Maxisorp,
Thermo Fisher Scientific, United Kingdom) were coated with 50 l/well
of human recombinant monoclonal fragment capture antibody (HuCAL
bivalent boIL-2 Fab antibody fragments containing a heavy-chain C-ter-
minal dHLX-dimerization domain followed by myc and 6His tag [Fab-
dHLX-MH, AbD14385] AbD [Serotec, United Kingdom]) diluted to 4
g/ml in carbonate coating buffer (Sigma, United Kingdom) (pH 9.6)
and incubated overnight at 4°C. Plates were blocked with 200 l/well of
4% bovine serum albumin (BSA)-phosphate buffered saline (PBS) (BSA;
Sigma, United Kingdom) for 1 h at RT, and washed three times with
PBS-0.05% Tween 20. Supernatants were added in duplicate, 50l/well. A
1% concentration of BSA-PBS (50l/well) was used as a negative control,
while 50l/well of recombinant bovine IL-2 (R&D Systems, United King-
dom) diluted to 10 ng/ml in 1% BSA-PBS was used as a positive control.
Plates were incubated for 2 h at RT (or overnight at 4°C) and washed 3
times with PBS-0.05% Tween 20 and 50l/well of biotinylated goat-anti-
bovine IL-2 antibody (R&D Systems, United Kingdom), diluted to 1
g/ml in 1% BSA/PBS, was added for 1 h at RT. Wells were washed as
above, and 50 l/well of streptavidin-horseradish peroxidase (HRP) (GE
Healthcare, Amersham, United Kingdom) diluted 1:2,000 in 1% BSA-
PBS was added for 1 h at RT. Wells were then washed six times and 100
l/well of tetramethylbenzidine (TMB) substrate (Sigma, United King-
dom) was added. Plates were allowed to develop for 20 min before adding
100 l/well of 0.5 M H2S04. Plates were read immediately on an ELISA
reader at a 450-nm wavelength. Results are expressed as the
OD 450 nm
(i.e., mean OD of duplicates in the presence of antigen/mitogen minus the
mean OD of duplicates in the absence of antigen/mitogen).
Statistics. Prism software was used for group comparisons and re-
ceiver operating characteristic (ROC) analysis of data (GraphPad, San
Diego, CA). Group comparisons were made using a 2-tailed Mann-Whit-
ney nonparametric statistical test.
RESULTS
Antigen-specific IL-2 responses in SICCT-positive naturally in-
fected cattle, but not inBCG-vaccinated or control cattle. Figure
1 shows the IL-2 and IFN- responses to PPDB, ESAT6-CFP10
(EC), and SEB or PWM for 33 naturally infected reactor cattle, 31
cattle vaccinated with M. bovis BCG, and 31 uninfected controls.
Antigen-specific IL-2 responses to PPDB and to EC were ob-
served only in the naturally infected reactor group (Fig. 1a). IL-2
responses to mitogen (either PWM or SEB) in all three groups
(Fig. 1, a to c) showed that cells were viable and produced IL-2
when stimulated nonspecifically. The complete absence of detect-
able antigen-specific IL-2 in both BCG-vaccinated (Fig. 1b) and
control (Fig. 1c) animals was in contrast to the positive PPDB-
specific IFN- responses observed in the BCG-vaccinated animals
(Fig. 1e) and control (Fig. 1f) groups, albeit significantly lower
than responses in reactor cattle (P 0.0001). M. bovis BCG vac-
cination is known to induce positive IFN- (and skin test) re-
sponses to PPDB, which excludes the use of PPDB as a DIVA
antigen. The IFN- responses to PPDB observed in control ani-
mals were probably reflective of cross-reactivity with environ-
mental mycobacterial antigens, since these animals had been
shown to be IFN- negative in previous IFN- tests that used the
differential responses to PPDB (M. bovis) and avian PPD (PPDA)
(Mycobacterium avium) as the test readout (data not shown).
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There were no positive IFN- responses to EC in the vaccinated
group (Fig. 1e), as expected, but four control animals did show
low positive responses to this peptide cocktail (Fig. 1f). Responses
to EC may occur due to the presence of these antigens in the
environmental mycobacterium Mycobacterium kansasii (17–20).
The data for IL-2 suggest that PPDB-stimulated IL-2 could
provide an alternative tool for differentiating vaccinated from in-
fected cattle. ROC analysis of the IL-2 data in this small study
suggested that using a positive/negative OD test cutoff of 0.1 (450
nm) would provide a 100% specificity (95% confidence interval
[CI], 88.78 to 100) and sensitivities of 93.9% (95% CI, 79.77 to
99.26) and 66.7% (95% CI, 48.17 to 82.04) for PPDB and EC,
respectively. None of the BCG-vaccinated cattle results would
have been positive using these cutoff criteria.
The sensitivity of EC-specific (but not PPDB-specific) IL-2 in
the reactor cohort could be increased without reducing the 100%
specificity (in the negative-control cohort) by lowering the cutoff,
e.g., an OD cutoff of 0.05 provided a sensitivity of 75.7% (95% CI,
57.74 to 88.91). However, lowering the cutoff generated positivity
in the BCG-vaccinated group, e.g., 3/31 (9.7%) positives at this
lower cutoff.
Low IL-2 positivity in SICCT-negative-IFN--positive field
reactor cattle. We next investigated PPDB-specific IL-2 responses
in a cohort of SICCT	/IFN- animals that had been identified
via routine blood testing of breakdown herds in Great Britain.
Sixty-six SICCT	/IFN- animals were compared with a further
64 TB-free control cattle. Since blood testing in Great Britain is
applied in parallel with the SICCT (i.e., SICCT animals were
removed and then the remaining animals were blood tested), we
were interested to know how an IL-2 test would compare against
the IFN- test using the above 0.1 OD cutoff for optimum sensi-
tivity and specificity. The results in Fig. 2 show that 30.3% (20/66)
of the IFN--positive cattle also produced a PPDB-specific IL-2
response. The specificity was 100% in that none of the control
animals produced positive IL-2 responses. These data suggest that
in animals that would be routinely blood tested in the event of a
confirmed TB breakdown, an IL-2 test would not be as sensitive as
the IFN- test. This was confirmed when we compared IL-2 pos-
FIG 1 IL-2 (a through c) and IFN- (d through f) responses to PPDB, ESAT6-CFP10 (EC), and a mitogen positive control (PWM or SEB). Each spot represents
a single animal.
FIG 2 PPDB-specific responses in naturally infected SICCT-negative/IFN--
positive reactor cattle (grouped into those with visible lesions [VL] and non-
visible lesions [NVL] at postmortem) and TB-free controls. Each spot repre-
sents a single animal. The 0.1-OD cutoff for optimal sensitivity/specificity
(from ROC analysis of IL-2 data in Fig. 1) is shown.
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itivity to the postmortem (PM) status of the SICCT	/IFN- an-
imals that were slaughtered as IFN- reactors. Of the 66 animals in
this group, we obtained PM data for 64 (37 with visible lesions
[VL] and 27 with nonvisible lesions [NVL]). We found that just 14
(37.8%) of the 37 VL cattle were IL-2, while 5 (18.5%) of the 27
NVL cattle were IL-2. However, this meant that of the IL-2
cattle for which we had PM data (n  19), 14 (73.7%) were VL,
while 5 (26.3%) were NVL, suggesting a higher VL capture rate in
IFN- animals with a positive IL-2 test outcome than in those
with a negative IL-2 test outcome. Note that in Great Britain the
IFN- surveillance test is applied only to herds undergoing a con-
firmed breakdown (identified by an M. bovis culture-positive in-
dex case). Additional cultures on further test-positive animals
from that breakdown are not required unless there is a specific
reason for doing so. Therefore, mycobacterial culture data for this
group of cattle are not available.
In terms of IL-2 test quality control criteria, we found that the
application of sample-positive (PWM stimulation) and negative-
control (unstimulated) cutoffs used for the IFN- test would be
equally viable for the IL-2 test, with only 3/130 (2.3%) animals
failing the positive control and 2/130 (1.5%) failing the negative
control. These data are shown as Fig. S1 in the supplemental ma-
terial, and they compare favorably with fail rates for routine IFN-
testing. For example, in 2012 there was a 1.5% positive-control fail
rate and a 1.8% negative-control fail rate.
Vaccine-induced IL-2 response following challenge with
pathogenic M. bovis. (i) Experiment 1. Fig. 3 shows the PPDB-
specific IL-2 (Fig. 3a) and IFN- (Fig. 3b) responses from BCG
vaccination/M. bovis challenge experiment 1. This experiment in-
cluded 16 vaccinated animals plus 8 unvaccinated challenge con-
trols. Whole-blood supernatants were tested post-BCG/pre-M.
bovis challenge (week 0) and then 2, 4, 6, and 8 weeks postchal-
lenge.
IL-2 responses (Fig. 3a) in the BCG-vaccinated group were
negligible before M. bovis challenge (day 0) but were positive and
significantly higher than those of the challenge control group at 2
weeks postinfection (P  0.002). While the IL-2 response of this
vaccinated group increased over time, the levels remained signif-
icantly lower throughout than those of the unvaccinated challenge
control group (P 0.005 at all time points). Levels of IL-2 in the
challenge control group were detected by 4 weeks postchallenge
and levels remained high thereafter to 8 weeks postchallenge.
On challenge with M. bovis, the IFN- response (Fig. 3b) of
vaccinated animals, already displaying a BCG-induced positive
response to PPDB on day 0 (the day of challenge), was boosted by
2 weeks postinfection and was significantly higher than the re-
sponse of the unvaccinated challenge controls at this time point
(P  0.0011). The response of unvaccinated challenge controls
was detected by 2 weeks postchallenge and thereafter increased,
significantly exceeding the levels of IFN- in the challenge control
group at 4 (P 0.002) and 6 (P 0.0011) weeks postinfection.
(ii) Experiment 2.We next investigated longitudinal responses
to BCG prior to M. bovis challenge, primarily to see if BCG alone,
at any point postvaccination, would induce an IL-2 response. Fig-
ure 4 shows the IL-2 (Fig. 4a) and IFN- (Fig. 4b) results from
vaccination and challenge experiment 2. While consisting of fewer
animals than experiment 1, the results demonstrated that IL-2 was
not induced during any time point post-BCG vaccination and
suggested that infection with pathogenic M. bovis is required to
stimulate a detectable PPDB-induced IL-2 response.
In contrast to the results of experiment 1, IL-2 responses in the
BCG-vaccinated group remained negligible until 4 weeks post-M.
bovis challenge. But in agreement with experiment 1, the levels of
IL-2 generated in unvaccinated control animals following chal-
lenge with M. bovis were significantly higher (*P  0.0159 at 4
weeks) than those induced in BCG-vaccinated and -challenged
cattle.
The IFN- results for experiment 2 (Fig. 4b) reflected those of
experiment 1 in that following M. bovis challenge, BCG-vacci-
nated animals produced a rapid IFN- response, observed at 2
weeks postchallenge, which was absent in challenge control cattle
(though not quite statistically significant in this experiment, P
0.0635). Once established, the IFN- response of the challenge
control group significantly exceeded the IFN- response of the
BCG-vaccinated group (*P 0.0159 at 4 weeks postchallenge).
The results of these two separate experiments suggest that the
priming of IL-2 by BCG vaccination may occur (experiment 1,
containing 24 cattle, showed statistically higher IL-2 in BCG-vac-
cinated cattle at 2 weeks post-M. bovis challenge). However, this
increase was not consistent across the two experiments. All of the
BCG-vaccinated animals in experiment 1 were protected follow-
ing challenge (pathology score for this group, mean  standard
error of the mean [SEM] of 0.833  0.386 compared to 15.0 
2.171 [16]), while just 2/5 BCG-vaccinated cattle in experiment 2
had a medium pathology score (9 and 11, respectively) (group
mean SEM of 4.8 2.27 compared to 18.5 5.84 in the chal-
lenge control group). A full description of the pathology scoring
method is described in Vordermeier et al. (21). Interestingly, the
FIG 3 IL-2 (a) and IFN- (b) responses to PPDB following M. bovis challenge
of BCG-vaccinated and unvaccinated animals (experiment 1). Data show the
group mean and standard error for each group at each time point (n  8
unvaccinated; n  16 BCG vaccinated). Significant differences in cytokine
levels between vaccinated and control groups are indicated.
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vaccinated animal with the highest pathology score of 11 in exper-
iment 2 also had the highest IL-2 response. These data collectively
suggest that IL-2, as well as IFN-, when measured postinfection
may correlate with the degree of pathology rather than protection.
DISCUSSION
This presence of PPDB-specific IL-2 responses in naturally in-
fected field reactor cattle when none were apparent in either M.
bovis BCG-vaccinated or uninfected controls provides the possi-
bility that IL-2 could make a useful addition to the DIVA test
toolbox to distinguish vaccinated from M. bovis-infected individ-
uals. Interestingly, it is the crude PPDB antigen that would be
required for this, since IL-2 stimulation by peptide cocktails (es-
sential for an IFN- DIVA test) had a much lower sensitivity in
infected cattle. PPDB-specific IL-2 responses, in contrast, could be
detected at a high sensitivity (93.9%) in SICCT/IFN- cattle, at
a somewhat lower sensitivity in SICCT	/IFN- cattle (30.3%),
and crucially within 4 weeks following experimental infection.
This study demonstrated that a high specificity (100%) of PPDB
antigen alone (i.e., without using PPDA) was possible.
That a positive IL-2 response may reflect the stage or degree of
infection was suggested by a higher VL identification rate in
SICCT	/IFN- cattle that were IL-2 positive; 73.7% of IL-2
cattle were VL, while 26.3% were NVL. Therefore, an IFN-/
IL-2 animal could be almost three time more likely to be VL than
NVL. Although, compared to the IFN- test, the IL-2 test was not
as sensitive in SICCT-negative animals compared to skin test-
positive animals, identifying just 30.3% of all the IFN- animals,
and 37.8% of the IFN- VL cattle. However, it is possible that
future improvement in the sensitivity to detect IL-2, for example
using enzyme-linked immunosorbent spot (ELISPOT) assay
read-outs (as we are currently investigating in our laboratory
[data not shown]) or a more sensitive system, such as Meso Scale
Discovery technology (which we already use in our laboratory to
detect other low-level cytokines, like IL-10 [22]) to quantify IL-2
in supernatants could enhance its overall test sensitivity.
The results of the BCG vaccination/M. bovis challenge studies
outlined the absence of (or inability to detect) IL-2 stimulation by
BCG vaccination alone, and the requirement of challenge by
pathogenic M. bovis before PPDB-specific IL-2 responses were
detected. Furthermore, and similar to IFN- responses, the IL-2
responses of BCG-vaccinated cattle following M. bovis infection
FIG 4 IL-2 (a) and IFN- (b) responses to PPDB following BCG vaccination and then challenge with M. bovis (experiment 2). Results are compared with those
of an unvaccinated challenge control group. Data show the group mean and standard error for each group at each time point (n 4 unvaccinated; n 5 BCG
vaccinated). Significantly higher IL-2 and IFN- levels were observed in challenge control cattle than in vaccinated cattle at 4 weeks after M. bovis challenge.
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were significantly lower than the IL-2 responses of unvaccinated
challenge controls. This suggests a relative modulation of antigen-
specific responses (IFN- and IL-2) in vaccinated/protected cat-
tle, and potential correlation of these responses with the degree of
pathology. In this way, and similar to IFN- (21), IL-2 could pres-
ent a marker of pathology, or advanced infection.
While some reports support this view in humanM. tuberculosis
infection (i.e., that T cells from people with advanced or active TB
only, but not latent TB, secrete IL-2 after specific stimulation [23,
24]), other reports suggest that the reverse may be true. Sester et al.
(25), using flow cytometry, and Casey et al. (26), using a dual-
purpose IFN-/IL-2 ELISPOT assay (both reports from the same
group), showed increases in T cells producing both IFN- and
IL-2, or IL-2 only in protected (BCG vaccinated, treated, or la-
tently infected) individuals and not in people with active TB who
had more T cells producing IFN-.
That BCG alone was unable to induce detectable specific IL-2
responses in our experiments is supported by other work in both
human TB and in mouse models. Peptides of the antigen Rv1986,
absent from commonly used BCG strains, stimulated strong IL-2-
positive T cell responses in M. tuberculosis-infected patients, and
deletion of this region from the M. tuberculosis bacillus led to
reduced IL-2 responsiveness (27). In mice, vaccination with a re-
combinant vaccine (Ag85B-ESAT6 plus CAF01) that gave better
protection against M. tuberculosis than BCG was found to induce
IL-2-positive multifunctional (TNF- and/or IFN-) T cells,
while BCG induced mainly IL-2-negative (TNF-/IFN-) T
cells (5). Furthermore, the time-dependent loss of BCG-mediated
protection against M. tuberculosis in this same mouse model that
was coincident with a decrease in IL-2-positive T cells was re-
versed by booster vaccination using the recombinant vaccine. The
authors suggest that the new vaccine stimulated central memory T
cells while BCG did not (11). If true, then this lends support to the
persistence of BCG in the host, rather than its generation of central
memory being responsible for any protection afforded by this vac-
cine.
In summary, we provide the first data for an IL-2 ELISA in
BTB, which suggests its use as a potential tool that could be opti-
mized and further developed for DIVA assays for the differentia-
tion of M. bovis infection following BCG vaccination and also
suggests that, as IL-2 production in vitro appeared more likely to
identify animals with visible gross pathology, an IL-2 test could
potentially provide useful information in addition to that of the
current BTB IFN- test.
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